1697-34-3

Basic information

• Product Name: 4-Methanesulfonyl morpholine
• Synonyms: 4-Methanesulfonyl morpholine;4-(METHYLSULFONYL)MORPHOLINE
• CAS NO: 1697-34-3
• Molecular Formula: C₅H₁₁NO₃S
• Molecular Weight: 165.21074
• Mol File: 1697-34-3.mol
• Article Data: 19

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Methanesulfonyl morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methanesulfonyl morpholine(1697-34-3)
• EPA Substance Registry System: 4-Methanesulfonyl morpholine(1697-34-3)

Safety Data

• Hazardous Substances Data: 1697-34-3(Hazardous Substances Data)

Usage

General Description

4-Methanesulfonyl morpholine is a chemical compound with the molecular formula C5H11NO3S. It is an organic compound that is commonly used as a reagent in organic synthesis and as an intermediate in the production of pharmaceuticals and agrochemicals. Its main use is as a reagent in the synthesis of sulfonyl chlorides and sulfonamides. It is a clear, colorless to pale yellow liquid with a faint, sweet odor. It is considered to be stable under normal conditions and is not highly reactive. However, it should be handled and stored with care, as it can cause irritation to the skin, eyes, and respiratory system upon contact or inhalation. It is also important to note that 4-Methanesulfonyl morpholine is not listed as a substance of concern by any major regulatory body.

Upstream product

• 110-91-8 morpholine 
• 67-68-5 dimethyl sulfoxide 
• 5765-65-1 4-(benzoyloxy)morpholine 
• 20277-69-4 sodium methansulfinate 
• 13368-42-8 4-(trimethylsilyl)morpholine 
• 124-63-0 methanesulfonyl chloride 
• 558-25-8 methyl fluorosulfonate 
• 4837-30-3 1-(methylthio)morpholine 
• 80284-02-2 N-nitromethanesulfonimide 
• 10383-49-0 methyl α-disulfone 

Downstream Products

• 19158-31-7 4-(phenylmethane)sulfonylmorpholine 
• 130178-85-7 4-[2-(4-Trifluoromethyl-phenyl)-ethynesulfonyl]-morpholine 
• 130178-88-0 4-[2-(4-Nitro-phenyl)-ethynesulfonyl]-morpholine 
• 130178-83-5 4-[2-(2,4-Dichloro-phenyl)-ethynesulfonyl]-morpholine 
• 130178-89-1 Dimethyl-[4-(morpholine-4-sulfonylethynyl)-phenyl]-amine 
• 130178-86-8 4-[2-(4-tert-Butyl-phenyl)-ethynesulfonyl]-morpholine 
• 130178-87-9 4-[2-(4-Methoxy-phenyl)-ethynesulfonyl]-morpholine 
• 130178-82-4 4-[2-(4-Chloro-phenyl)-ethynesulfonyl]-morpholine 
• 130178-84-6 4-[2-(4-Fluoro-phenyl)-ethynesulfonyl]-morpholine 
• 110380-99-9 P₉₀₃ 
• 92-52-4 biphenyl 
• 202286-54-2 9-isopropyl-7,12-dimethyl-3-(morpholinosulfonyl)benzo[a]heptalene-2,4-diol 
• 1026484-23-0 1-(4-morpholinylsulfonyl)-3-({4-[4-(trifluoromethoxy)phenoxy]phenyl}sulfanyl)acetone 
• 130179-04-3 2-(Morpholine-4-sulfonyl)-1-(4-nitro-phenyl)-ethanone 

Relevant articles and documents

Electrosynthesis of sulfonamides from DMSO and amines under mild conditions

With DMSO as the solvent and the precursor of a -SO2Me unit at room temperature, a novel electrochemical oxidization and amination of DMSO with amines was developed for the synthesis of sulfonamides. Our investigations reveal that this transformation may involve a radical process and an electrochemical oxidization of DMSO.

Selective caspase inhibitors and uses thereof

The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).

Copper-catalyzed electrophilic amination of sodium sulfinates at room temperature

By using O-benzoyl hydroxylamines as amine sources, the first convenient copper-catalyzed electrophilic amination of sodium sulfinates has been realized. Even with 2 mol% catalyst loading, the protocol provided an efficient and straightforward synthesis of a broad range of functional sulfonamides under ambient reaction conditions without an additional base and ligand. Based on the control experiments, a plausible mechanism was proposed.